Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

My Lifestyle Intervention of Food and Exercise
Preventing Breast Cancer Recurrence Through a Tailored Lifestyle Intervention.
Status: Enrolling
Updated:  10/8/2015
University of Florida
mi
from
Gainesville, FL
My Lifestyle Intervention of Food and Exercise
Preventing Breast Cancer Recurrence Through a Tailored Lifestyle Intervention.
Status: Enrolling
Updated: 10/8/2015
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
My Lifestyle Intervention of Food and Exercise
Preventing Breast Cancer Recurrence Through a Tailored Lifestyle Intervention.
Status: Enrolling
Updated:  10/8/2015
University of North Florida
mi
from
Jacksonville, FL
My Lifestyle Intervention of Food and Exercise
Preventing Breast Cancer Recurrence Through a Tailored Lifestyle Intervention.
Status: Enrolling
Updated: 10/8/2015
University of North Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence
Status: Enrolling
Updated:  10/8/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence
Status: Enrolling
Updated: 10/8/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated:  10/8/2015
California Cancer Associates for Research and Excellence
mi
from
Fresno, CA
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated: 10/8/2015
California Cancer Associates for Research and Excellence
mi
from
Fresno, CA
Click here to add this to my saved trials
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated:  10/8/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated: 10/8/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated:  10/8/2015
Palo Verde Hematology & Oncology
mi
from
Glendale, AZ
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated: 10/8/2015
Palo Verde Hematology & Oncology
mi
from
Glendale, AZ
Click here to add this to my saved trials
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated:  10/8/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated: 10/8/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated:  10/8/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated: 10/8/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated:  10/8/2015
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated: 10/8/2015
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated:  10/8/2015
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated: 10/8/2015
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Improving Colon Cancer Screening for Diverse Populations
The CHOICES/"OPCIONES Project: Improving Colon Cancer Screening for Diverse Populations
Status: Enrolling
Updated:  10/8/2015
University of New Mexico
mi
from
Albuquerque, NM
Improving Colon Cancer Screening for Diverse Populations
The CHOICES/"OPCIONES Project: Improving Colon Cancer Screening for Diverse Populations
Status: Enrolling
Updated: 10/8/2015
University of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Improving Colon Cancer Screening for Diverse Populations
The CHOICES/"OPCIONES Project: Improving Colon Cancer Screening for Diverse Populations
Status: Enrolling
Updated:  10/8/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Improving Colon Cancer Screening for Diverse Populations
The CHOICES/"OPCIONES Project: Improving Colon Cancer Screening for Diverse Populations
Status: Enrolling
Updated: 10/8/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Improving Colon Cancer Screening for Diverse Populations
The CHOICES/"OPCIONES Project: Improving Colon Cancer Screening for Diverse Populations
Status: Enrolling
Updated:  10/8/2015
Carolinas Healthcare Systems
mi
from
Charlotte, NC
Improving Colon Cancer Screening for Diverse Populations
The CHOICES/"OPCIONES Project: Improving Colon Cancer Screening for Diverse Populations
Status: Enrolling
Updated: 10/8/2015
Carolinas Healthcare Systems
mi
from
Charlotte, NC
Click here to add this to my saved trials
Changes in Muscle Tissue in Patients With Pancreatic Cancer
Pilot Study of Changes in Fat-Free Mass in Pancreatic Carcinoma Patients
Status: Enrolling
Updated:  10/8/2015
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Changes in Muscle Tissue in Patients With Pancreatic Cancer
Pilot Study of Changes in Fat-Free Mass in Pancreatic Carcinoma Patients
Status: Enrolling
Updated: 10/8/2015
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
Phase II Trial of Weekly Docetaxel (Taxotere) Vs. Weekly Docetaxel in Combination With ZD1839 (Iressa®) As Consolidation Therapy For Metastatic Urothelial Cancer Following Maximal Response To Multi-Agent Chemotherapy
Status: Enrolling
Updated:  10/8/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
Phase II Trial of Weekly Docetaxel (Taxotere) Vs. Weekly Docetaxel in Combination With ZD1839 (Iressa®) As Consolidation Therapy For Metastatic Urothelial Cancer Following Maximal Response To Multi-Agent Chemotherapy
Status: Enrolling
Updated: 10/8/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers
Improving the Quality of Advanced Cancer Care With Disease Management
Status: Enrolling
Updated:  10/8/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers
Improving the Quality of Advanced Cancer Care With Disease Management
Status: Enrolling
Updated: 10/8/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Status: Enrolling
Updated:  10/8/2015
Highlands Oncology Group DeptofHighlandsOncologyGrp(2)
mi
from
Fayetteville, AR
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Status: Enrolling
Updated: 10/8/2015
Highlands Oncology Group DeptofHighlandsOncologyGrp(2)
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Status: Enrolling
Updated:  10/8/2015
Loma Linda Oncology Medical Group Loma Linda
mi
from
Redlands, CA
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Status: Enrolling
Updated: 10/8/2015
Loma Linda Oncology Medical Group Loma Linda
mi
from
Redlands, CA
Click here to add this to my saved trials
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Status: Enrolling
Updated:  10/8/2015
Henry Ford Hospital Dept. of Henry Ford Hospital
mi
from
Detroit, MI
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Status: Enrolling
Updated: 10/8/2015
Henry Ford Hospital Dept. of Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Status: Enrolling
Updated:  10/8/2015
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Status: Enrolling
Updated: 10/8/2015
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Status: Enrolling
Updated:  10/8/2015
University of Texas Southwestern Medical Center DeptofSimmons Cancer Center(4)
mi
from
Dallas, TX
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Status: Enrolling
Updated: 10/8/2015
University of Texas Southwestern Medical Center DeptofSimmons Cancer Center(4)
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Status: Enrolling
Updated:  10/8/2015
The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD(2)
mi
from
Fort Worth, TX
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Status: Enrolling
Updated: 10/8/2015
The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD(2)
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Status: Enrolling
Updated:  10/8/2015
University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology
mi
from
Houston, TX
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Status: Enrolling
Updated: 10/8/2015
University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Status: Enrolling
Updated:  10/8/2015
University of Washington Cancer Care Seattle Cancer Alliance
mi
from
Seattle, WA
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Status: Enrolling
Updated: 10/8/2015
University of Washington Cancer Care Seattle Cancer Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Status: Enrolling
Updated:  10/8/2015
Novartis Investigative Site
mi
from
Rio Negro,
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Status: Enrolling
Updated: 10/8/2015
Novartis Investigative Site
mi
from
Rio Negro,
Click here to add this to my saved trials
Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer
Isolation and Identification of Lung Cancer Precursor Cells From Malignant Pleural Effusion Specimens
Status: Enrolling
Updated:  10/8/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer
Isolation and Identification of Lung Cancer Precursor Cells From Malignant Pleural Effusion Specimens
Status: Enrolling
Updated: 10/8/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Identifying Circulating Breast Cancer Cells in Women With Metastatic Breast Cancer
A Feasibility Study of a Novel Technique to Identify Circulating Breast Cancer Cells in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  10/9/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Identifying Circulating Breast Cancer Cells in Women With Metastatic Breast Cancer
A Feasibility Study of a Novel Technique to Identify Circulating Breast Cancer Cells in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 10/9/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian Cancer
Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian Cancer
Status: Enrolling
Updated:  10/9/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian Cancer
Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian Cancer
Status: Enrolling
Updated: 10/9/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Assessment of Ability of Breath Hold for Left-sided Breast Cancer Radiation Therapy to Reduce Side Effects to Heart
Prospective Pilot Study of Assessment of Breath Hold as a Means to Mitigate the Risk of Radiation-associated Reductions in Regional Cardiac Perfusion in Patients With Left-sided Breast Cancer
Status: Enrolling
Updated:  10/9/2015
University of North Carolina at Chapel Hill, Department of Radiation Oncology
mi
from
Chapel Hill, NC
Assessment of Ability of Breath Hold for Left-sided Breast Cancer Radiation Therapy to Reduce Side Effects to Heart
Prospective Pilot Study of Assessment of Breath Hold as a Means to Mitigate the Risk of Radiation-associated Reductions in Regional Cardiac Perfusion in Patients With Left-sided Breast Cancer
Status: Enrolling
Updated: 10/9/2015
University of North Carolina at Chapel Hill, Department of Radiation Oncology
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Tumor Motion Management in Radiotherapy Using 4D-MRI
Evaluation of Tumor Motion Management Strategies in Radiotherapy Using 4D-MRI
Status: Enrolling
Updated:  10/9/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Tumor Motion Management in Radiotherapy Using 4D-MRI
Evaluation of Tumor Motion Management Strategies in Radiotherapy Using 4D-MRI
Status: Enrolling
Updated: 10/9/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Doxercalciferol Before Surgery in Treating Localized Prostate Cancer
Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN
Status: Enrolling
Updated:  10/9/2015
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Doxercalciferol Before Surgery in Treating Localized Prostate Cancer
Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN
Status: Enrolling
Updated: 10/9/2015
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Doxercalciferol Before Surgery in Treating Localized Prostate Cancer
Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN
Status: Enrolling
Updated:  10/9/2015
James P. Wilmot Cancer Center at University of Rochester Medical Center
mi
from
Rochester, NY
Doxercalciferol Before Surgery in Treating Localized Prostate Cancer
Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN
Status: Enrolling
Updated: 10/9/2015
James P. Wilmot Cancer Center at University of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Doxercalciferol Before Surgery in Treating Localized Prostate Cancer
Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN
Status: Enrolling
Updated:  10/9/2015
Veterans Affairs Medical Center - Madison
mi
from
Madison, WI
Doxercalciferol Before Surgery in Treating Localized Prostate Cancer
Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN
Status: Enrolling
Updated: 10/9/2015
Veterans Affairs Medical Center - Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Doxercalciferol Before Surgery in Treating Localized Prostate Cancer
Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN
Status: Enrolling
Updated:  10/9/2015
Meriter Hospital, Inc.
mi
from
Madison, WI
Doxercalciferol Before Surgery in Treating Localized Prostate Cancer
Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN
Status: Enrolling
Updated: 10/9/2015
Meriter Hospital, Inc.
mi
from
Madison, WI
Click here to add this to my saved trials
Doxercalciferol Before Surgery in Treating Localized Prostate Cancer
Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN
Status: Enrolling
Updated:  10/9/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Doxercalciferol Before Surgery in Treating Localized Prostate Cancer
Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN
Status: Enrolling
Updated: 10/9/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Doxercalciferol Before Surgery in Treating Localized Prostate Cancer
Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN
Status: Enrolling
Updated:  10/9/2015
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Doxercalciferol Before Surgery in Treating Localized Prostate Cancer
Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN
Status: Enrolling
Updated: 10/9/2015
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated:  10/9/2015
UCLA Medical Center
mi
from
Los Angeles, CA
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated: 10/9/2015
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated:  10/9/2015
Wilshire Oncology Medical Group, Inc.
mi
from
Pomona, CA
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated: 10/9/2015
Wilshire Oncology Medical Group, Inc.
mi
from
Pomona, CA
Click here to add this to my saved trials
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated:  10/9/2015
Cancer Institute Of Florida
mi
from
Orlando, FL
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated: 10/9/2015
Cancer Institute Of Florida
mi
from
Orlando, FL
Click here to add this to my saved trials
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated:  10/9/2015
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated: 10/9/2015
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Click here to add this to my saved trials
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated:  10/9/2015
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated: 10/9/2015
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Click here to add this to my saved trials
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated:  10/9/2015
Cross Cancer Institute
mi
from
Edmonton,
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Status: Enrolling
Updated: 10/9/2015
Cross Cancer Institute
mi
from
Edmonton,
Click here to add this to my saved trials
Capecitabine in Treating Patients With Metastatic Breast Cancer
Phase II Study of Fixed-Dose Capecitabine in Metastatic Breast Cancer
Status: Enrolling
Updated:  10/9/2015
DeCesaris Cancer Institute at Anne Arundel Medical Center
mi
from
Annapolis, MD
Capecitabine in Treating Patients With Metastatic Breast Cancer
Phase II Study of Fixed-Dose Capecitabine in Metastatic Breast Cancer
Status: Enrolling
Updated: 10/9/2015
DeCesaris Cancer Institute at Anne Arundel Medical Center
mi
from
Annapolis, MD
Click here to add this to my saved trials
Capecitabine in Treating Patients With Metastatic Breast Cancer
Phase II Study of Fixed-Dose Capecitabine in Metastatic Breast Cancer
Status: Enrolling
Updated:  10/9/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Capecitabine in Treating Patients With Metastatic Breast Cancer
Phase II Study of Fixed-Dose Capecitabine in Metastatic Breast Cancer
Status: Enrolling
Updated: 10/9/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Capecitabine in Treating Patients With Metastatic Breast Cancer
Phase II Study of Fixed-Dose Capecitabine in Metastatic Breast Cancer
Status: Enrolling
Updated:  10/9/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Capecitabine in Treating Patients With Metastatic Breast Cancer
Phase II Study of Fixed-Dose Capecitabine in Metastatic Breast Cancer
Status: Enrolling
Updated: 10/9/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
A Phase 2 Study of AZD2171 in Patients With Recurrent Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
Status: Enrolling
Updated:  10/9/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
A Phase 2 Study of AZD2171 in Patients With Recurrent Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
Status: Enrolling
Updated: 10/9/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery
Effects of Surgery, Radiation Therapy, Chemotherapy, and Endocrine Therapy on High-Sensitivity C-Reactive Protein in Women With Operable Breast Cancer
Status: Enrolling
Updated:  10/9/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery
Effects of Surgery, Radiation Therapy, Chemotherapy, and Endocrine Therapy on High-Sensitivity C-Reactive Protein in Women With Operable Breast Cancer
Status: Enrolling
Updated: 10/9/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Trial of Acupuncture for Reduction of Post-Colectomy Ileus
A Phase II Randomized Controlled Trial of Acupuncture for Reduction of Post-Colectomy Ileus
Status: Enrolling
Updated:  10/9/2015
Memorial Sloan-Kettering Cancer Center 1275 York Avenue
mi
from
New York, NY
Trial of Acupuncture for Reduction of Post-Colectomy Ileus
A Phase II Randomized Controlled Trial of Acupuncture for Reduction of Post-Colectomy Ileus
Status: Enrolling
Updated: 10/9/2015
Memorial Sloan-Kettering Cancer Center 1275 York Avenue
mi
from
New York, NY
Click here to add this to my saved trials
Collecting Information From Patients Enrolled in the Breast Specialized Program of Research Excellence
The Breast Cancer Specialized Program of Research Excellence (SPORE): Core A-Administrative/Biostatistics Core
Status: Enrolling
Updated:  10/11/2015
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Collecting Information From Patients Enrolled in the Breast Specialized Program of Research Excellence
The Breast Cancer Specialized Program of Research Excellence (SPORE): Core A-Administrative/Biostatistics Core
Status: Enrolling
Updated: 10/11/2015
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer
A Phase II Study of Active Immunotherapy With PANVAC or Autologous, Cultured Dendritic Cells Infected With PANVAC After Complete Resection of Hepatic or Pulmonary Metastases of Colorectal Carcinoma
Status: Enrolling
Updated:  10/11/2015
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington,
Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer
A Phase II Study of Active Immunotherapy With PANVAC or Autologous, Cultured Dendritic Cells Infected With PANVAC After Complete Resection of Hepatic or Pulmonary Metastases of Colorectal Carcinoma
Status: Enrolling
Updated: 10/11/2015
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials